Digital Therapeutics Market
Digital Therapeutics/DTx Market by Offering (Software, Immersive), Application (Treatment (Diabetes, CNS, CVD, Rehab), Preventive), Revenue (Subscription, Enterprise), Channel (B2B, B2C), End User (Hospitals, Payers, Employers) - Global Forecast to 2031
DIGITAL THERAPEUTICS MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global digital therapeutics market is projected to grow from USD 10.95 billion in 2026 to USD 35.37 billion by 2031, at a CAGR of 26.4% during the forecast period. The market was valued at USD 8.83 billion in 2025. The digital therapeutics market is driven by the increasing adoption of evidence-based digital interventions to improve clinical outcomes, enable remote patient management, and reduce healthcare costs. Growing use of AI-powered therapeutics, wearable-integrated solutions, and personalized digital care is accelerating market growth.
KEY TAKEAWAYS
-
MARKET SNAPSHOT:
Base Year Market Size (2025): USD 8.83 Billion
Current Market Size (2026): USD 10.95 Billion
Forecast Market Size (2031): USD 35.37 Billion
CAGR (2026–2031): 26.4% -
SEGMENT LEADERSHIP:
Regional Leader: North America accounted for the largest share of 47.6% of the digital therapeutics market in 2025.
Offering Leader: Immersive & interface-based therapeutics segment is expected to register the highest CAGR of 28.7% during the forecast period.
Product Type Leader: Prescription digital therapeutics segment dominated the market in 2025.
Application Leader: Preventive applications segment is expected to register the highest CAGR during the forecast period.
Revenue Model Leader: Outcome-/value-based model segment is expected to register the highest CAGR during the forecast period.
Sales Channel Leader: B2B sales channel segment dominated the market with a share of 73.6% in 2025.
End User Leader: Healthcare providers segment is expected to dominate the market from 2026 to 2031. -
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
Teladoc Health, Inc., Noom, Inc., and Hinge Health, Inc. were identified as some of the star players in the global digital therapeutics market, given their strong market share and product footprint.
Freespira and Mindable Health GmbH have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The digital therapeutics industry is driven by the growing demand for clinically validated, software-based interventions that improve patient outcomes while reducing healthcare costs. The rising prevalence of chronic diseases, increasing adoption of remote patient monitoring and AI-enabled personalized care, and the shift toward value-based healthcare are encouraging healthcare providers, payers, employers, and pharmaceutical companies to integrate digital therapeutics into disease prevention, management, and treatment to enhance patient engagement, improve treatment adherence, and optimize long-term clinical outcomes.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
There has been a significant transformation in the digital therapeutics market, with a shift from standalone mobile health and wellness applications to clinically validated, AI-enabled, and integrated digital therapeutic platforms. Vendors have evolved from basic disease management solutions to advanced capabilities such as personalized digital interventions, remote patient monitoring, wearable-integrated therapeutics, digital biomarkers, immersive technologies (VR/AR), and real-world data analytics. Growing demand from healthcare providers, payers, employers, pharmaceutical companies, and patients is accelerating market adoption. As healthcare increasingly shifts toward value-based and patient-centric care, next-generation digital therapeutics are becoming essential for improving patient engagement, treatment adherence, clinical outcomes, and long-term disease management.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Rising prevalence of chronic and behavioral health conditions

-
Shift toward value-based and patient-centered care
Level
-
Limited reimbursement and inconsistent payment pathways
-
Regulatory complexity and evolving approval frameworks
Level
-
Expansion into new therapeutic areas
-
Integration with AI and personalized medicine
Level
-
Sustaining long-term patient engagement and adherence
-
Demonstrating long-term clinical and economic value
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Rising prevalence of chronic and behavioral health conditions
The rising prevalence of chronic and behavioral health conditions is a key driver of the digital therapeutics market. The increasing burden of diseases such as diabetes, cardiovascular disorders, obesity, chronic respiratory diseases, musculoskeletal disorders, and mental health conditions is creating a growing need for scalable, evidence-based care beyond traditional healthcare settings. Digital therapeutics enable continuous disease management through personalized interventions, behavioral modification, remote patient monitoring, and medication adherence support. As healthcare systems increasingly focus on improving long-term clinical outcomes while reducing the burden on healthcare infrastructure, the adoption of digital therapeutics is accelerating across healthcare providers, payers, employers, and patients.
Restraint: Limited reimbursement and inconsistent payment pathways
Limited reimbursement and inconsistent payment pathways continue to restrain the growth of the digital therapeutics market. While clinical evidence supporting digital therapeutics is expanding, reimbursement policies vary significantly across countries, healthcare systems, and payer organizations, creating uncertainty for developers and healthcare providers. Many digital therapeutics are not yet included in standard insurance coverage or national reimbursement programs, limiting patient access and slowing adoption. In addition, the lack of standardized reimbursement frameworks and value assessment criteria makes it challenging for companies to demonstrate economic benefits and secure broad payer coverage, thereby affecting the commercialization and scalability of digital therapeutics.
Opportunity: Expansion into new therapeutic areas
The expansion of digital therapeutics into new therapeutic areas presents a significant growth opportunity for the market. While digital therapeutics have gained strong adoption in diabetes, mental health, and musculoskeletal disorders, companies are increasingly developing clinically validated solutions for cardiovascular diseases, oncology, women's health, gastrointestinal disorders, neurological diseases, sleep disorders, and rare diseases. Advances in artificial intelligence (AI), digital biomarkers, wearable technologies, and real-world evidence are enabling the development of personalized interventions for a broader range of acute and chronic conditions. As clinical evidence and regulatory acceptance continue to expand, digital therapeutics are expected to complement conventional therapies across multiple disease areas, creating new commercial opportunities for developers and improving access to evidence-based digital care.
Challenge: Sustaining long-term patient engagement and adherence
Sustaining long-term patient engagement and adherence remains a significant challenge for the digital therapeutics market. The effectiveness of digital therapeutics depends on consistent patient participation over extended periods; however, maintaining user motivation and regular usage can be difficult due to declining engagement, digital fatigue, varying levels of health literacy, and behavioral barriers. In addition, limited personalization, complex user interfaces, and inadequate integration with routine clinical care may further reduce adherence. Addressing these challenges requires continuous innovation in personalized interventions, AI-driven coaching, gamification, and seamless integration with healthcare workflows to ensure sustained patient participation and optimal clinical outcomes.
DIGITAL THERAPEUTICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
AI-enabled virtual care, chronic disease management, remote patient monitoring (RPM), and integrated digital therapeutics platform | Improved patient engagement, reduced hospitalizations, enhanced chronic disease outcomes, and expanded access to virtual care |
|
|
AI-powered behavior change platform, digital weight management, nutrition coaching, and personalized lifestyle interventions | Sustainable weight loss, improved metabolic health, higher patient adherence, and reduced risk of chronic diseases |
|
|
AI-driven musculoskeletal (MSK) digital therapy, wearable-enabled motion tracking, computer vision, and virtual physical therapy | Faster recovery, reduced pain, lower musculoskeletal treatment costs, and decreased need for surgery or opioid use |
|
|
Digital chronic disease prevention and management platform for diabetes, hypertension, obesity, and cardiovascular health using connected devices and personalized coaching | Improved clinical outcomes, better disease control, increased medication adherence, and reduced healthcare expenditures |
|
|
AI-powered digital therapeutics platform integrating glucose monitoring, blood pressure monitoring, behavioral health, and personalized coaching | Better disease self-management, improved patient outcomes, enhanced engagement, and lower total cost of care |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The digital therapeutics market ecosystem consists of leading providers such as Teladoc Health, Omada Health, Hinge Health, DarioHealth, Click Therapeutics, WellDoc, and Sidekick Health, which offer clinically validated software solutions for chronic disease management, behavioral health, musculoskeletal care, and remote patient monitoring. Emerging companies such as Wellthy Therapeutics, AppliedVR, XRHealth, and Canary Health are advancing AI-enabled personalized therapeutics, immersive (VR/XR)-based interventions, and digital behavioral health solutions. Technology providers, including Amazon Web Services (AWS), Microsoft Azure, Google Cloud, Apple, and Google, support scalable cloud infrastructure, artificial intelligence, data analytics, and connected health ecosystems. End users, including healthcare providers, payers, employers, pharmaceutical & life sciences companies, diagnostic & rehabilitation centers, academic & research institutes, and patients, leverage these solutions to improve clinical outcomes, enhance patient engagement, support remote care, and reduce overall healthcare costs.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Digital Therapeutics Market, by Offering
In 2025, the software/platforms segment accounted for the largest share of the digital therapeutics market, as software platforms serve as the core infrastructure for delivering evidence-based therapeutic interventions, monitoring patient outcomes, and enabling continuous disease management. These platforms provide personalized treatment programs, behavioral coaching, real-time data collection, remote patient monitoring, and seamless communication between patients and healthcare providers through mobile applications and web-based interfaces. The increasing adoption of digital-first healthcare models, rising prevalence of chronic diseases, and growing demand for scalable, clinically validated treatment solutions have significantly strengthened the adoption of software platforms. Additionally, ongoing advancements in artificial intelligence, predictive analytics, cloud-based architectures, interoperability with electronic health records (EHRs), and integration with wearable and connected medical devices have enhanced the clinical effectiveness and accessibility of digital therapeutics. These capabilities continue to drive investments in software platforms, enabling healthcare stakeholders to improve patient engagement, optimize clinical outcomes, and deliver cost-effective care at scale.
Digital Therapeutics Market, by Product Type
The prescription digital therapeutics (PDTx) segment accounted for the largest share of the digital therapeutics market in 2025, driven by the growing adoption of clinically validated digital therapies for managing chronic and behavioral health conditions such as diabetes, mental health disorders, insomnia, and substance use disorders. Strong clinical evidence, regulatory approvals, and expanding reimbursement support have accelerated adoption among healthcare providers and payers. Furthermore, increasing integration with remote patient monitoring platforms, electronic health records, and connected medical devices has strengthened the use of prescription digital therapeutics, enabling the segment to maintain its leading market position.
Digital Therapeutics Market, by Application
The treatment & care-related applications segment accounted for the largest share of the global digital therapeutics market in 2025, driven by the increasing adoption of digital therapeutics for managing chronic and behavioral health conditions such as diabetes, cardiovascular diseases, mental health disorders, respiratory diseases, and musculoskeletal conditions. The growing need for continuous disease management, improved treatment adherence, and remote patient monitoring has accelerated the use of evidence-based digital therapeutic solutions across healthcare settings. Additionally, expanding clinical validation, integration with connected health technologies, and increasing support from healthcare providers and payers have further strengthened the segment's leading market position.
Digital Therapeutics Market, by Revenue Model
The subscription-based model segment accounted for the largest share of the global digital therapeutics market in 2025, driven by its ability to provide continuous access to digital therapeutic programs, personalized coaching, and ongoing patient support through recurring payment plans. This model offers predictable revenue streams for solution providers while enabling healthcare organizations, employers, payers, and individual users to access scalable and cost-effective care. Its flexibility, affordability, and support for long-term disease management have accelerated adoption across chronic disease, mental health, and wellness applications. Additionally, increasing demand for continuous patient engagement and regular software updates has further strengthened the dominance of subscription-based digital therapeutics.
Digital Therapeutics Market, by Sales Channel
The B2B (business-to-business) segment held the largest share of the digital therapeutics market in 2025, primarily due to the strong adoption of these solutions by healthcare providers, payers, employers, and pharmaceutical companies. Unlike direct-to-consumer offerings, B2B deployments are supported through enterprise contracts, reimbursement programs, and institutional partnerships, enabling large-scale implementation across patient populations. The increasing focus on value-based care, population health management, and reducing long-term healthcare costs has encouraged organizations to integrate digital therapeutics into clinical care pathways and employee health programs. As a result, the B2B sales channel continues to generate the highest revenue, supported by long-term contracts, broader patient reach, and expanding collaborations across the healthcare ecosystem.
Digital Therapeutics Market, by End User
The healthcare providers segment accounted for the largest share of the digital therapeutics market in 2025, driven by the increasing integration of digital therapeutics into routine clinical practice for the management of chronic diseases, mental health conditions, and rehabilitation. Hospitals, specialty clinics, and other healthcare facilities are increasingly prescribing and monitoring digital therapeutics to improve treatment adherence, enable continuous patient monitoring, and support personalized care. The growing adoption of integrated digital health platforms, coupled with the shift toward value-based care and remote care delivery, has further strengthened the role of healthcare providers as the largest end-user segment in the market.
REGION
Asia Pacific is projected to register the highest CAGR during the forecast period (2026-2031)
The Asia Pacific region is one of the fastest-growing markets for digital therapeutics due to the rising prevalence of chronic diseases, rapid healthcare digitalization, increasing smartphone and internet penetration, and growing adoption of AI-enabled digital health solutions. Furthermore, supportive government initiatives, expanding telehealth and remote patient monitoring infrastructure, increasing investments in digital health startups, and the growing focus on preventive and value-based care are accelerating the adoption of digital therapeutics across the region.

DIGITAL THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX
In the market matrix for the digital therapeutics market, Teladoc Health, Inc. (Star) stands out with high market revenue and a comprehensive digital care portfolio, supported by its strong presence across virtual care, chronic disease management, mental health, remote patient monitoring, and AI-enabled digital health solutions. Its broad global customer base, integrated care ecosystem, strategic acquisitions, and strong partnerships with healthcare providers, payers, and employers reinforce its leadership position in the digital therapeutics market. Click Therapeutics, Inc. (Emerging Leader) has gained recognition through its clinically validated prescription digital therapeutics (PDTs), robust clinical evidence generation, and collaborations with leading pharmaceutical companies to develop software-based therapeutic interventions across multiple disease areas. While Teladoc Health leads through its scale, portfolio breadth, global reach, and established commercial presence, Click Therapeutics demonstrates strong potential to move toward the leaders' quadrant as demand for prescription digital therapeutics, AI-enabled personalized care, and evidence-based software interventions continues to expand across healthcare systems.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Teladoc Health, Inc. (US)
- Noom, Inc. (US)
- Omada Health Inc. (US)
- Hinge Health, Inc. (US)
- DarioHealth Corp. (US)
- Sword Health, Inc. (Portugal)
- Virta Health Corp (US)
- Welldoc, Inc. (US)
- Click Therapeutics, Inc. (US)
- Resmed (US)
- Sidekick Health (Iceland)
- Akili, Inc. (US)
- AppliedVR, Inc. (US)
- Wellthy Therapeutics Pvt Ltd (India)
- Headspace Inc. (US)
- Lark Technologies, Inc. (US)
- XRHealth (US)
- Amalgam Rx, Inc. (US)
- Aptar Digital Health (France)
- Canary Health (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 8.83 BN |
| Market Size in 2026 (Value) | USD 10.95 BN |
| Market Forecast in 2031 (Value) | USD 35.37 BN |
| Growth Rate | 26.4% |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
WHAT IS IN IT FOR YOU: DIGITAL THERAPEUTICS MARKET REPORT CONTENT GUIDE

DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Local Competitive Landscape | Profiling of leading digital therapeutics companies based on therapeutic focus, AI capabilities, clinical evidence, reimbursement, partnerships, and product portfolio | Enables competitive benchmarking, vendor evaluation, and differentiation strategies |
| Regional Market Entry Strategy | Assessment of regional adoption, reimbursement landscape, healthcare digitization, and market maturity across key geographies | Supports localization, reduces entry risk, and identifies high-growth markets |
| Local Risk & Opportunity Assessment | Analysis of reimbursement, regulatory landscape, clinical evidence requirements, adoption barriers, and growth opportunities | Strengthens risk mitigation and supports investment decisions |
| Technology Adoption by Region | Mapping adoption of AI-enabled DTx, remote patient monitoring, wearable-integrated therapeutics, digital biomarkers, and immersive therapeutics across end users | Identifies technology trends and supports product development and market expansion |
RECENT DEVELOPMENTS
- June 2026 : DarioHealth announced a strategic collaboration with Beluga Health to deliver provider-backed, integrated cardiometabolic and behavioral health care by combining Dario's AI-powered digital therapeutics platform with Beluga Health's virtual care capabilities, enabling scalable, personalized chronic disease management.
- April 2026 : Noom, Humana, and Welldoc partnered with b.well Connected Health to expand secure health data access and interoperability, enabling members to integrate longitudinal health records with personalized digital therapeutics and chronic disease management solutions.
- January 2026 : Sword Health acquired Kaia Health to strengthen its AI-powered digital musculoskeletal care portfolio, expand into mental health, and accelerate global growth through an integrated, end-to-end digital care platform.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This research study involved the extensive use of both primary and secondary sources. It involved the analysis of various factors affecting the industry to identify the segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.
Secondary Research
This research study extensively utilized secondary sources, including directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, as well as white papers, annual reports, and companies' house documents. The secondary research aimed to gather and analyze information for a comprehensive and commercially focused study of the digital therapeutics market, encompassing technical aspects and market dynamics. It also facilitated the identification of key players, market classification, industry trends, geographical markets, and significant market-related developments. Additionally, a database of prominent industry leaders was compiled through secondary research.
Primary Research
In the primary research process, various supply-side and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, engineers, and related key executives from various companies and organizations operating in the digital therapeutics market. Primary sources from the demand side included personnel from healthcare providers, payers, employees, and patients/individuals.

Others include sales managers, marketing managers, and product managers.
Note: Tiers are defined based on a company’s total revenue, as of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the digital therapeutics market was determined after data triangulation through the two approaches mentioned below. After the completion of each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.
Global Digital Therapeutics Market Size: Top-down Approach and Bottom-up Approach

Data Triangulation
The size of the digital therapeutics market was estimated through segmental extrapolation using the bottom-up approach. The methodology used is as given below:
- Revenues for individual companies were gathered from public sources and databases.
- Shares of leading players in the digital therapeutics market were gathered from secondary sources to the extent available. In certain cases, shares of digital therapeutics businesses have been ascertained after a detailed analysis of various parameters, including product portfolios, market positioning, selling price, and geographic reach & strength.
- Individual shares or revenue estimates were validated through interviews with experts.
- The total revenue in the digital therapeutics market was determined by extrapolating the market share data of major companies.
Market Definition
The digital therapeutics market comprises evidence-based, clinically validated software solutions designed to prevent, manage, or treat medical conditions through therapeutic interventions delivered via digital technologies. These solutions are delivered through mobile applications, web-based platforms, connected devices, and immersive technologies, and may be prescribed by healthcare professionals or accessed directly by consumers. By leveraging data analytics, artificial intelligence (AI), and personalized behavioral interventions, digital therapeutics improve clinical outcomes, enhance patient engagement, and support the prevention and management of acute and chronic diseases.
Key Stakeholders
- Digital therapeutics developers and platform providers
- Pharmaceutical and biotechnology companies
- Healthcare providers (hospitals, specialty clinics, rehabilitation centers, and primary care centers)
- Health insurance companies (public and private payers)
- Employers and corporate wellness providers
- Medical device and wearable technology companies
- Academic medical centers, universities, and research institutions
- Regulatory agencies and health technology assessment (HTA) bodies
- Government and public health organizations
- Telehealth and digital health platform providers
- Electronic health record (EHR) and healthcare IT solution providers
- Investors, venture capital firms, and private equity firms
- Patients and patient advocacy organizations
- Business research and consulting service providers
Report Objectives
- To define, describe, and forecast the digital therapeutics market based on offering, product type, application, revenue model, sales channel, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall digital therapeutics market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments such as product launches & approvals, partnerships, agreements, and collaborations in the overall digital therapeutics market
- To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy.
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
Geographic Analysis
- Further breakdown of the Rest of Asia Pacific digital therapeutics market into Taiwan, New Zealand, Thailand, Singapore, Malaysia, and other countries
- Further breakdown of the Rest of Europe digital therapeutics market into Russia, Austria, Finland, Sweden, Turkey, Norway, Poland, Portugal, Romania, Denmark, and other countries
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Digital Therapeutics/DTx Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
Growth opportunities and latent adjacency in Digital Therapeutics/DTx Market
Michael
Mar, 2022
Which is the fastest growing market of Digital Therapeutics Market?.
David
Mar, 2022
Which are the key factors driving the growth of the Global Digital Therapeutics Market?.
William
Mar, 2022
What are the growth estimates for Digital Therapeutics Market till 2026?.